Provided by Tiger Trade Technology Pte. Ltd.

Mesoblast

14.74
-0.2800-1.86%
Post-market: 14.740.00000.00%16:10 EDT
Volume:182.50K
Turnover:2.68M
Market Cap:1.91B
PE:-33.20
High:14.80
Open:14.80
Low:14.59
Close:15.02
52wk High:21.50
52wk Low:13.05
Shares:129.69M
Float Shares:84.12M
Volume Ratio:1.03
T/O Rate:0.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4440
EPS(LYR):-0.4441
ROE:-9.86%
ROA:-4.11%
PB:3.36
PE(LYR):-33.19

Loading ...

Mesoblast Hits Phase 3 Recruitment Milestone in Chronic Back Pain Push

TIPRANKS
·
Apr 29

Mesoblast Details April Equity Issuance Moves and Director Share Purchases

TIPRANKS
·
Apr 17

Mesoblast Reports Lapse of 723,666 Options, Reducing Potential Dilution

TIPRANKS
·
Apr 16

Mesoblast Seeks ASX Quotation for 3.05 Million New Shares

TIPRANKS
·
Apr 16

Mesoblast Issues 815,000 Unquoted Options Under Employee Incentive Scheme

TIPRANKS
·
Apr 16

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Galmed Pharmaceuticals (GLMD), Neurocrine (NBIX) and Mesoblast (MESO)

TIPRANKS
·
Apr 15

Sector Update: Health Care

MT Newswires Live
·
Apr 15

Mesoblast Acquires Exclusive License to Chimeric Antigen Receptor Platform; Shares Up 7%

MT Newswires Live
·
Apr 15

BRIEF-Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products

Reuters
·
Apr 15

Mesoblast Secures CAR Platform to Sharpen Targeting of Cell Therapies

TIPRANKS
·
Apr 15

Mesoblast Ltd - Obtains Worldwide Exclusive Rights to Car-MSC Ip From Mayo Clinic

THOMSON REUTERS
·
Apr 15

Mesoblast Ltd - to Incorporate Engineered Cars to Enhance Product Specificity

THOMSON REUTERS
·
Apr 15

Mesoblast Insider Makes Bold Multimillion-Dollar Move Into Company Stock

TIPRANKS
·
Apr 14

Top Mesoblast Insider Makes Massive New Bet on the Company’s Future

TIPRANKS
·
Apr 11

Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION

GlobeNewswire
·
Apr 11

Mesoblast (MESO) Gets a Buy from Piper Sandler

TIPRANKS
·
Apr 10

Mesoblast's Fiscal 2026 Net Revenue Projected to be Up to $120 Million, Jefferies Says

MT Newswires Live
·
Apr 10

Assessing Mesoblast’s Valuation After FDA Clears New Ryoncil Trial In Duchenne Muscular Dystrophy

Simply Wall St.
·
Apr 09

Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation

GlobeNewswire
·
Apr 08

Mesoblast's Duchenne Muscular Dystrophy Treatment Heads for US Registrational Clinical Trial; Shares Up Pre-Bell

MT Newswires Live
·
Apr 08